Promising new treatment for asthma flare-ups for the first time in 50 years
A new way to treat asthma and COPD flare-ups could be a "game-changer," researchers say. A new study, published in The Lancet today, has investigated the use of high-tech biologic therapy Benralizumab (Fasenra) in treating acute asthma exacerbations. Benralizumab (Fasenra) works by targeting white blood cells that cause inflammation. Already used in regular low doses to treat severe asthma, researchers have now tested its efficacy in tackling asthma attacks using a single high-dose injection. Early studies suggest this new use of the drug cuts the need for further treatment by 30%.
